已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma

索拉非尼 医学 肝细胞癌 危险系数 内科学 实体瘤疗效评价标准 肝癌 肿瘤科 经导管动脉化疗栓塞 胃肠病学 随机对照试验 随机化 置信区间 肝功能 进行性疾病 化疗
作者
Masatoshi Kudo,Kazuomi Ueshima,Masafumi Ikeda,Takuji Torimura,Nobukazu Tanabe,Hiroshi Aikata,Namiki Izumi,Takahiro Yamasaki,Shunsuke Nojiri,Keisuke Hino,Hidetaka Tsumura,Teiji Kuzuya,Norio Isoda,Michihisa Moriguchi,Hajime Aino,Akio Ido,Naoto Kawabe,Kazuhiko Nakao,Yoshiyuki Wada,Sadahisa Ogasawara,Kenichi Yoshimura,Takuji Okusaka,Junji Furuse,Norihiro Kokudo,Kiwamu Okita,Philip J. Johnson,Yasuaki Arai
出处
期刊:Liver cancer [Karger Publishers]
卷期号:11 (4): 354-367 被引量:72
标识
DOI:10.1159/000522547
摘要

<b><i>Introduction:</i></b> Several clinical trials comparing the efficacy and safety of transarterial chemoembolization (TACE) plus molecular-targeted agents versus TACE alone revealed no clinical benefits in progression-free survival (PFS) or overall survival (OS). Here, we report the final OS analysis from the TACTICS trial, which previously demonstrated significant improvement in PFS with TACE plus sorafenib in patients with unresectable hepatocellular carcinoma (HCC) (NCT01217034). <b><i>Methods:</i></b> Patients with unresectable HCC were randomized to a TACE plus sorafenib group (<i>N</i> = 80) or a TACE alone group (<i>N</i> = 76). Patients in the combination treatment group received sorafenib 400 mg once daily for 2–3 weeks before TACE, followed by 800 mg once daily during on-demand conventional TACE sessions until time to untreatable progression. In this trial, TACE-specific PFS was used. TACE-specific PFS is defined as the time from randomization to progressive disease (PD) or death from any cause, and PD was defined as untreatable progression, caused by the inability of a patient to further receive or benefit from TACE for reasons that include intrahepatic tumor progression (25% increase vs. baseline) according to response evaluation criteria in cancer of the liver, the detection of extrahepatic spread, vascular invasion, or transient deterioration of liver function to Child-Pugh C after TACE. <b><i>Results:</i></b> At the cut-off date of July 31, 2020, 131 OS events were observed. The median OS was 36.2 months with TACE plus sorafenib and 30.8 months with TACE alone (hazard ratio [HR] = 0.861; 95% confidence interval [CI], 0.607–1.223; <i>p</i> = 0.40, ΔOS, 5.4 months). The updated PFS was 22.8 months with TACE plus sorafenib and 13.5 months with TACE alone (HR = 0.661; 95% CI, 0.466–0.938; <i>p</i> = 0.02). Post-trial treatments with active procedures/agents were received by 47 (58.8%) patients in the TACE plus sorafenib group and 58 (76.3%) in the TACE alone group (<i>p</i> = 0.01). In post hoc analysis, PFS and OS benefit were shown in HCC patients with tumor burden beyond up-to-7 criteria. <b><i>Conclusions:</i></b> In TACTICS trial, TACE plus sorafenib did not show significant OS benefit over TACE alone; however, clinical meaningful OS prolongation and significantly improved PFS was observed. Thus, the TACE plus sorafenib can be considered a choice of treatment in intermediate-stage HCC, especially in patients with high tumor burden. Trial Registration: NCT01217034.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wiky完成签到,获得积分10
1秒前
大个应助ma采纳,获得10
1秒前
希特勒完成签到,获得积分20
1秒前
zhongu发布了新的文献求助10
1秒前
1秒前
万能图书馆应助HongY采纳,获得10
3秒前
3秒前
Lidocaine完成签到,获得积分10
3秒前
希特勒发布了新的文献求助10
6秒前
8秒前
8秒前
1218完成签到 ,获得积分10
11秒前
16秒前
17秒前
苏和杨发布了新的文献求助10
19秒前
nicenice发布了新的文献求助10
19秒前
19秒前
20秒前
21秒前
万能图书馆应助称心嫣娆采纳,获得10
22秒前
23秒前
深情安青应助苏和杨采纳,获得10
24秒前
27秒前
田様应助orange9采纳,获得10
29秒前
完美世界应助然大宝采纳,获得10
30秒前
Arui发布了新的文献求助10
32秒前
33秒前
大模型应助丰富钢铁侠采纳,获得10
33秒前
34秒前
Zhanghh87发布了新的文献求助10
34秒前
35秒前
我是老大应助mellow采纳,获得10
38秒前
momo发布了新的文献求助10
38秒前
dabao应助不喜采纳,获得10
38秒前
贰鸟应助Muhammad采纳,获得10
39秒前
漂亮白枫发布了新的文献求助10
39秒前
42秒前
iNk应助Sky36001采纳,获得20
43秒前
龙金兴完成签到 ,获得积分10
43秒前
46秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989797
求助须知:如何正确求助?哪些是违规求助? 3531914
关于积分的说明 11255516
捐赠科研通 3270597
什么是DOI,文献DOI怎么找? 1805008
邀请新用户注册赠送积分活动 882181
科研通“疑难数据库(出版商)”最低求助积分说明 809190